Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Kimball Electronics (Nasdaq: KE) expanded its Board of Directors by appointing Tom Vadaketh as a new director effective September 13, 2022. Mr. Vadaketh, currently the Chief Financial Officer of Bausch Health (NYSE:BHC), will serve on the Audit Committee and stand for election at the upcoming Annual Meeting in November 2022. With extensive experience in finance and leadership roles in multinational organizations, his addition is expected to enhance the Board's skill set and contribute to the company's growth and stakeholder relationships.
Bausch Health Companies Inc. (NYSE/TSX: BHC) reported on September 14, 2022, the results of its Exchange Offers to exchange existing senior notes valued at up to $4 billion for new secured notes. As of September 13, 2022, holders had tendered approximately $5,577,725,000 in existing notes. The exchange is expected to result in approximately $3,119 million in new secured notes, comprising new first and second lien notes. The Offers will expire on September 27, 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the FDA's tentative approval of Norwich Pharmaceuticals' rifaximin 200 mg product, classified under a Paragraph III filing. The approval will not lead to full authorization until July 24, 2029, when the last of Bausch's patents for XIFAXAN expires. Currently, XIFAXAN contributes less than 1% of Salix's revenues. XIFAXAN is used to treat travelers' diarrhea and has additional indications for major gastrointestinal conditions.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced clarifications regarding its Exchange Offers to exchange existing senior notes for new secured notes. Key points include that Eligible Holders waiving rights related to the exchanged notes and retaining rights under unsold notes. The Offers are exclusively for specific eligible investors, including non-U.S. persons and qualified institutional buyers. All other terms of the Offers remain unchanged. Interested Eligible Holders are encouraged to consult the Exchange Offer Memorandum for full details.
Bausch Health Companies announced the commencement of Exchange Offers to exchange existing senior notes for new secured notes totaling up to $4 billion. The new notes include $2.5 billion in 11% First Lien Secured Notes due 2028 and $500 million in 14% Second Lien Secured Notes due 2030. A support agreement has been signed by holders representing 22.8% of existing notes. The offers will expire on September 27, 2022, with an early tender deadline on September 13, 2022. Investors should assess the details in the Exchange Offer Memorandum.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has transferred approximately 38.6% of its issued shares in Bausch + Lomb Corporation to a wholly-owned unrestricted subsidiary. The Company retains 50.1% of Bausch + Lomb, maintaining an overall 88.7% ownership. This transfer aligns with Bausch Health's plan for the separation of Bausch + Lomb, providing strategic flexibility while evaluating options. The separation is subject to lockup expirations, debt leverage ratios, and necessary approvals.
KBRA has released its latest U.S. Bank Compendium, analyzing the 2Q22 results for U.S. banks rated by KBRA amidst rising interest rates. The report discusses how banks are adjusting to these changes and potential impacts on profitability amid economic uncertainty. Key performance metrics, including credit ratios and returns on assets, are highlighted. The Compendium also provides a quarterly ESG Bulletin featuring Univest Financial Corporation (NASDAQ: UVSP) along with summaries of all publicly traded banks in KBRA's rated universe.
Bausch Health Companies (NYSE/TSX: BHC) announced that the U.S. District Court in Delaware upheld certain patents for XIFAXAN® (rifaximin) 550 mg while invalidating others. The company plans to appeal this decision, with expectations for the appeal to conclude in 12 to 18 months. Currently, Norwich Pharmaceuticals cannot launch a generic version of XIFAXAN until it receives FDA approval for a revised application that excludes the XIFAXAN HE indication. XIFAXAN is indicated for treating IBS-D and preventing hepatic encephalopathy recurrence.
Bausch Health Companies Inc. (BHC) announced support for the new ICD-10 code K76.82 for hepatic encephalopathy (HE), effective October 1, 2022. This code aims to enhance diagnosis and treatment for the rising number of chronic liver disease cases in the U.S., where approximately 4.5 million adults are affected. HE, a complication of cirrhosis, can lead to increased hospitalizations and readmissions. The new code will assist healthcare providers in accurately documenting HE, thereby improving patient care.
Bausch Health Companies Inc. reported second-quarter 2022 revenues of $1.967 billion, down 6% from $2.1 billion in Q2 2021. The decline was attributed to foreign exchange impacts and divestitures. The company's net loss decreased to $145 million compared to $595 million the previous year. Operating income improved significantly to $161 million. Bausch Health is appealing a court decision concerning XIFAXAN patent litigation and is committed to strategic alternatives, including a potential spinoff of Bausch + Lomb, despite ongoing challenges.